MARKET

SYRS

SYRS

Syros Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.740
-0.140
-2.87%
Closed 17:38 07/29 EDT
OPEN
4.870
PREV CLOSE
4.880
HIGH
4.880
LOW
4.715
VOLUME
363.44K
TURNOVER
--
52 WEEK HIGH
15.65
52 WEEK LOW
4.350
MARKET CAP
293.21M
P/E (TTM)
-2.8706
1D
5D
1M
3M
1Y
5Y
Will Syros Pharmaceuticals, Inc. (SYRS) Report Negative Q2 Earnings? What You Should Know
Zacks.com · 12h ago
Syros to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 5, 2021 to report its second quarte...
Business Wire · 20h ago
Were Hedge Funds Right About Syros Pharmaceuticals, Inc. (SYRS)?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under manageme...
Insider Monkey · 3d ago
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 07/16 11:37
Is Syros Pharmaceuticals (NASDAQ:SYRS) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Simply Wall St. · 06/29 11:01
SAFM, WISH, MVIS and MNOV among after-hours movers
Gainers: [[SAFM]] +9.2%. [[WISH]] +5.7%. [[GBS]] +3.5%. [[LOTZ]] +3.4%. [[SYRS]] +2.5%.Losers: [[MVIS]] -10.7%. [[BIDU]] -7.0%. [[MNOV]] -5.5%. [[FOCS]] -4.9%. [[CNCE]] -4.3%.
Seekingalpha · 06/21 21:40
BRIEF-Elevation Oncology Announces Appointment Of Joseph Ferra As Chief Financial Officer
reuters.com · 06/17 11:34
BRIEF-Syros Pharmaceuticals - On June 7, Joseph J. Ferra, Jr., Notified Co Of His Decision To Resign From His Position As CFO Effective June 15
reuters.com · 06/10 12:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYRS. Analyze the recent business situations of Syros Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYRS stock price target is 16.57 with a high estimate of 20.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 131
Institutional Holdings: 65.92M
% Owned: 106.56%
Shares Outstanding: 61.86M
TypeInstitutionsShares
Increased
44
8.87M
New
17
1.55M
Decreased
29
2.37M
Sold Out
12
816.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.26%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman/Independent Director
Peter Wirth
President/Chief Executive Officer/Chief Financial Officer/Director
Nancy Simonian
Chief Scientific Officer
Eric Olson
Other
Gerald Quirk
Other
David Roth
Director
Richard Young
Independent Director
Srinivas Akkaraju
Independent Director
Mark Alles
Independent Director
S. Gail Eckhardt
Independent Director
Marsha Fanucci
Independent Director
Amir Nashat
Independent Director
Phillip Sharp
No Data
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefining the power of small molecules to control the expression of genes. It is focused on developing treatments for cancer and diseases resulting from mutations of a single gene (monogenic diseases) and building a pipeline of gene control medicines. Its product candidates include SY-1425, SY-5609 and SY-2101. SY-1425 is a selective retinoic acid receptor alpha (RAR), agonist that is being evaluated in combination with azacytidine, used to treat acute myeloid leukemia (AML). SY-5609 is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors. SY-2101 is an oral form of arsenic trioxide (ATO) being developed for the treatment of AML.

Webull offers kinds of Syros Pharmaceuticals Inc stock information, including NASDAQ:SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYRS stock methods without spending real money on the virtual paper trading platform.